Journal of Clinical & Experimental Pharmacology

Peter J Little

Publications

• Research Article
  Sodium Fusidate Inhibits rCYP3A4 in vitro-A Possible Mechanism Defining the Interaction with Statins
  Author(s): Daniel Guidone, Robel Getachew, Narin Osman, Michael Ward, Vincent Chan and Peter J LittleDaniel Guidone, Robel Getachew, Narin Osman, Michael Ward, Vincent Chan and Peter J Little
  
  Sodium fusidate (fusidic acid) is an antimicrobial agent used to treat methicillin-resistant Staphylococcus aureus infections. Several case reports have described drug interactions between sodium fusidate and CYP3A4 metabolised statins, leading to statin myotoxicity, including fatal myotoxicity. The mechanism of this interaction is unknown. We investigated the effects of sodium fusidate on recombinant CYP3A4 in vitro and found it to be a timedependent inhibitor of this enzyme at concentrations likely to be achieved with clinical dosing regimens. This finding may help to explain the mechanism of the apparent statin-fusidate interaction. Introduction Sodium fusidate (fusidic acid) is a naturally occurring antibiotic derived from the fungus Fusidium coccineum. It has a narrow antimicrobial spectrum, exhibiting particular activity against Staphylococcus aureus [1]. Sodium fusidate exhibit.. View More»
  DOI: 10.4172/2161-1459.1000174

  Abstract PDF